Matinas Biopharma Holdings, Inc. (NYSE:MTNB – Get Free Report) shares traded up 5.3% during trading on Wednesday . The company traded as high as $0.75 and last traded at $0.69. 154,059 shares traded hands during mid-day trading, a decline of 18% from the average session volume of 188,216 shares. The stock had previously closed at $0.65.
Matinas Biopharma Price Performance
The stock’s fifty day moving average price is $0.58. The company has a market capitalization of $3.50 million, a PE ratio of -0.14 and a beta of 1.19.
About Matinas Biopharma
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D.
Featured Stories
- Five stocks we like better than Matinas Biopharma
- What is the Dow Jones Industrial Average (DJIA)?
- SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start
- Health Care Stocks Explained: Why You Might Want to Invest
- AMD’s AI-Powered Stock Price Rally Just Shifted Gears
- What Are Earnings Reports?
- 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
